TAVR: News & Clinical Trials

Apr 22nd, 2022
Clinical Interest Article

ADAPT-TAVR Trial—Coverage of ACC.22

Routine Use of Edoxaban Post-TAVR in Patients Without an Indication for Anticoagulation Does Not Significantly Reduce Valve Thrombosis or Stroke